探究减瘤手术对合并远处转移的上尿路尿路上皮癌患者预后的影响

doi:10.3969/j.issn.1006-7795.2024.02.023

摘要/Abstract

摘要： 目的探究减瘤手术对合并远处转移的上尿路尿路上皮癌患者预后的影响。方法筛选2010年1月至2015年12月SEER 数据库中已经发生远处转移的上尿路尿路上皮癌患者的临床数据, 根据是否行减瘤手术分为减瘤手术组和未做减瘤手术组，比较组间基线差异。通过单因素和多因素 Cox 比例风险回归模型分析与已经发生远处转移的上尿路尿路上皮癌患者生存有关的预后影响因素。通过 Kaplan-Meier 法绘制生存曲线分析各组的生存情况。结果本研究共纳入患者238例，减瘤手术者157例，未做减瘤手术者81例，总体基线较为平稳。单因素和多因素Cox回归分析结果显示：减瘤手术、化学药物治疗（以下简称化疗）、肝转移是总生存期（overall survival, OS）的独立风险因素；减瘤手术和化疗是癌症特异性生存期（cancer special survival, CSS）的独立风险因素。Kaplan-Meier曲线显示：年龄、减瘤手术、化疗、肝转移与OS密切相关；减瘤手术、化疗、肝转移与CSS密切相关。结论对于已经发生远处转移的上尿路尿路上皮癌患者，减瘤手术可明显改善患者预后，减瘤手术、化疗、肝转移是总生存结局的独立影响因素，减瘤手术和化疗是疾病相关生存结局的独立影响因素。

关键词: 上尿路尿路上皮癌, 远处转移, 减瘤手术, 预后, SEER

Abstract: Objective To explore the effect of tumor reduction surgery on the prognosis of upper urinary tract urothelial cancer patients with distant metastasis. Methods The clinical data of upper urinary tract urothelial cancer patients with distant metastasis were screened in SEER database from January 2010 to December 2015. According to whether tumor reduction surgery was performed or not, the patients were divided into two groups： tumor reduction operation group and non-tumor reduction operation group. Univariate and multivariate Cox proportional hazard regression models were used to analyze the prognostic factors related to the survival of upper urinary tract urothelial cancer patients with distant metastasis. The survival curve was drawn by Kaplan-Meier method to analyze the survival condition of each group. Results A total of 238 patients were included in this study, 157 patients underwent tumor reduction surgery and 81 patients did not. The overall baseline was relatively stable. Cox univariate analysis showed that tumor reduction surgery, chemotherapy, liver metastasis were independent risk factors for overall survival（ OS）, while tumor reduction surgery and chemotherapy were independent risk factors for cancer special survival（CSS）. Kaplan-Meier curve showed that tumor reduction surgery, chemotherapy and liver metastasis were closely related to OS, while tumor reduction surgery, chemotherapy and liver metastasis were closely related to CSS. Conclusion For patients with upper urinary tract urothelial carcinoma with distant metastasis, tumor reduction surgery can significantly improve the prognosis. Tumor reduction surgery, chemotherapy, and liver metastasis are independent factors affecting the overall survival outcome. Tumor reduction surgery and chemotherapy are independent factors affecting the cancer special survival outcome.

Key words: upper tract urothelial carcinoma, metastasis, reduction surgery, prognosis, SEER

中图分类号:

R737

赵昱, 张荣杰, 陈元浩, 李高, 矫宾宾, 张鑫. 探究减瘤手术对合并远处转移的上尿路尿路上皮癌患者预后的影响[J]. 首都医科大学学报, 2024, 45(2): 340-347.

Zhao Yu, Zhang Rongjie, Chen Yuanhao, Li Gao, Jiao Binbin, Zhang Xin. Exploring the effect of tumor reduction surgery on the prognosis of upper tract urothelial carcinoma patients with metastasis[J]. Journal of Capital Medical University, 2024, 45(2): 340-347.

参考文献

［1］ Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update［J］. Eur Urol, 2021, 79(1): 62-79.
［2］ Rouprêt M, Seisen T, Birtle A J, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update［J］. Eur Urol, 2023, 84(1): 49-64.
［3］ Favaretto R L, Shariat S F, Chade D C, et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center［J］. Eur Urol, 2010, 58(4): 574-580.
［4］ Cheaib J G, Claus L E, Patel H D, et al. Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma［J］. Urol Oncol, 2021, 39(1): 74.e9-74.e16.
［5］ Soria F, Shariat S F, Lerner S P, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)［J］. World J Urol, 2017, 35(3): 379-387.
［6］ Davaro F, May A, McFerrin C, et al. Chemotherapy increases survival and downstaging of upper tract urothelial cancer［J］. Can J Urol, 2019, 26(5): 9938-9944.
［7］ Margulis V, Shariat S F, Matin S F, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration［J］. Cancer, 2009, 115(6): 1224-1233.
［8］ Raman J D, Messer J, Sielatycki J A, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005［J］. BJU Int, 2011, 107(7): 1059-1064.
［9］ Uprety D, Bista A, Smith A L, et al. Cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in the targeted therapy era［J］. Anticancer Res, 2018, 38(5): 3013-3018.
［10］ Culp S H, Schellhammer P F, Williams M B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study［J］. Eur Urol, 2014, 65(6): 1058-1066.
［11］ Flanigan R C, Salmon S E, Blumenstein B A, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer［J］. N Engl J Med, 2001, 345(23): 1655-1659.
［12］ Mickisch G H, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial［J］. Lancet, 2001, 358(9286): 966-970.
［13］ Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study［J］. J Urol, 2015, 193(3): 832-838.
［14］朱刚, 张凯. 原发灶减瘤根治性前列腺切除术治疗骨转移前列腺癌患者的现状及展望(附光盘)［J］. 现代泌尿外科杂志, 2017, 22(3): 162-164.
［15］ Comen E, Norton L, Massagué J. Clinical implications of cancer self-seeding［J］. Nat Rev Clin Oncol, 2011, 8(6): 369-377.
［16］ Kaplan RN, Rafii S, Lyden D. Preparing the “soil”: the premetastatic niche［J］. Cancer Res, 2006, 66(23): 11089-11093.

[1]	姜艳, 赵轩宇, 隋峰. 中-重度子宫内膜异位症特征基因筛选[J]. 首都医科大学学报, 2024, 45(2): 322-332.
[2]	徐晶星, 周全, 应建明. 肿瘤微环境在三阴性乳腺癌免疫治疗中的研究进展[J]. 首都医科大学学报, 2023, 44(5): 882-888.
[3]	叶小波, 熊天宇, 朱光艺, 张慧博, 金木兰, 杨敏福, 邢念增, 牛亦农. 腹腔镜下根治性前列腺切除术后的肿瘤学和功能学结局：10年随访[J]. 首都医科大学学报, 2023, 44(3): 424-432.
[4]	朱光艺, 王润锦, 熊天宇, 叶小波, 刘占良, 曹放, 林哲闽, 牛亦农. 非转移性前列腺癌根治术后发生第二原发癌的危险因素分析[J]. 首都医科大学学报, 2023, 44(3): 433-438.
[5]	王润锦, 叶小波, 张玉冬, 朱光艺, 杨坤, 牛亦农. 不同侵袭模式对T3a肾细胞癌患者预后的影响[J]. 首都医科大学学报, 2023, 44(3): 439-448.
[6]	张玉冬, 魏后忆, 王润锦, 蒋铭心, 杨坤, 王明帅, 瓦斯里江·瓦哈甫, 宋黎明, 金木兰, 邢念增, 牛亦农. 回肠通道术术前营养控制状态评分对判断膀胱癌患者预后的价值[J]. 首都医科大学学报, 2023, 44(3): 449-456.
[7]	熊天宇, 牛亦农. 前列腺周围脂肪组织影响前列腺癌发展的机制[J]. 首都医科大学学报, 2023, 44(3): 457-462.
[8]	杨一凡, 王雅梅. 凋亡诱导因子2在乳腺癌中的表达及其相关作用[J]. 首都医科大学学报, 2023, 44(2): 248-257.
[9]	王文文, 蔡昱, 贾双双, 翟建军. 驱动蛋白家族成员2C与卵巢癌化学药物治疗耐药的相关性[J]. 首都医科大学学报, 2023, 44(1): 143-147.
[10]	刘群, 李丽娜, 刘健, 苗劲蔚. 卵巢癌SOX4介导TGF-β1诱导的上皮间质转化对侵袭转移能力的影响[J]. 首都医科大学学报, 2022, 43(3): 336-342.
[11]	田明, 孔秋, 候晓晓, 苗劲蔚. 良、恶性卵巢甲状腺肿的临床和病理特征分析[J]. 首都医科大学学报, 2022, 43(3): 343-349.
[12]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[13]	蒋铭心, 苏瑶, 熊天宇, 叶小波, 靳松, 邢念增, 金木兰, 杨敏福, 牛亦农. 减瘤性根治性前列腺切除术对骨转移前列腺癌患者的临床疗效分析[J]. 首都医科大学学报, 2021, 42(6): 967-972.
[14]	王明帅, 熊天宇, 蒋铭心, 钱小松, 王思豪, 崔韵, 牛亦农. 改良前列腺尖部分离技术保留尿道周围结构对前列腺癌根治术后即刻尿控的影响[J]. 首都医科大学学报, 2021, 42(6): 973-977.
[15]	叶小波, 熊天宇, 崔韵, 王明帅, 杨辉, 安卓玲, 牛亦农. 醋酸阿比特龙联合强的松治疗去势抵抗型前列腺癌的疗效分析[J]. 首都医科大学学报, 2021, 42(6): 978-985.